Jacobs Levy Equity Management’s Ionis Pharmaceuticals IONS Stock Holding History

Jacobs Levy Equity Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,813	Closed	-$269K	–	1035
2025 Q2	$269K	Buy	+6,813	New	+$223K	﹤0.01%	947
2025 Q1	–	Sell	-281,813	Closed	-$9.85M	–	1139
2024 Q4	$9.85M	Sell	281,813 -368,966	-57%	-$13.8M	0.03%	308
2024 Q3	$26.1M	Buy	650,779 +77,909	+14%	+$3.62M	0.1%	191
2024 Q2	$27.3M	Buy	572,870 +1,107	+0.2%	+$45.4K	0.11%	182
2024 Q1	$24.8M	Buy	571,763 +62,230	+12%	+$2.97M	0.11%	186
2023 Q4	$25.8M	Buy	509,533 +136,416	+37%	+$6.53M	0.13%	174
2023 Q3	$16.9M	Sell	373,117 -176,441	-32%	-$7.28M	0.1%	200
2023 Q2	$22.5M	Buy	549,558 +12,870	+2%	+$495K	0.13%	180
2023 Q1	$19.2M	Sell	536,688 -153,033	-22%	-$5.75M	0.12%	196
2022 Q4	$26.1M	Buy	689,721 +177,746	+35%	+$7.48M	0.18%	157
2022 Q3	$22.6M	Sell	511,975 -104,791	-17%	-$4.42M	0.18%	150
2022 Q2	$22.8M	Sell	616,766 -1,001,501	-62%	-$37.8M	0.18%	148
2022 Q1	$59.9M	Buy	1,618,267 +210,879	+15%	+$6.9M	0.4%	59
2021 Q4	$42.8M	Buy	1,407,388 +216,152	+18%	+$6.8M	0.29%	89
2021 Q3	$40M	Buy	1,191,236 +106,814	+10%	+$4.02M	0.27%	97
2021 Q2	$43.3M	Buy	1,084,422 +921,476	+566%	+$36.1M	0.29%	92
2021 Q1	$7.33M	Sell	162,946 -41,235	-20%	-$2.3M	0.06%	349
2020 Q4	$11.5M	Buy	204,181 +54,709	+37%	+$2.73M	0.1%	232
2020 Q3	$7.09M	Sell	149,472 -8,027	-5%	-$446K	0.07%	277
2020 Q2	$9.29M	Buy	157,499 +51,922	+49%	+$2.89M	0.1%	230
2020 Q1	$4.99M	Buy	105,577 +20,853	+25%	+$1.16M	0.06%	293
2019 Q4	$5.12M	Sell	84,724 -72,116	-46%	-$4.3M	0.05%	369
2019 Q3	$9.4M	Buy	156,840 +44,770	+40%	+$2.92M	0.12%	222
2019 Q2	$7.2M	Buy	112,070 +59,380	+113%	+$4.2M	0.1%	263
2019 Q1	$4.28M	Buy	+52,690	New	+$3.4M	0.06%	357
2016 Q3	–	Sell	-136,900	Closed	-$3.19M	–	1068
2016 Q2	$3.19M	Buy	+136,900	New	+$4.42M	0.07%	338
2015 Q2	–	Sell	-5,740	Closed	-$365K	–	826
2015 Q1	$365K	Buy	5,740 +500	+10%	+$33.9K	0.01%	621
2014 Q4	$324K	Sell	5,240 -2,320	-31%	-$114K	0.01%	666
2014 Q3	$294K	Buy	+7,560	New	+$268K	﹤0.01%	682

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's IONS Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 6,813 shares — an estimated $269K sold.

Jacobs Levy Equity Management first reported a position in IONS in Q3 2014 and held it in 29 quarters. The position peaked at $59.9M in Q1 2022. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

Jacobs Levy Equity Management reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 6,813 Ionis Pharmaceuticals shares in Q3 2025, an estimated $269K.
Jacobs Levy Equity Management first reported a position in Ionis Pharmaceuticals in Q3 2014 and held it in 29 quarters.
Jacobs Levy Equity Management's Ionis Pharmaceuticals position peaked at $59.9M in Q1 2022.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.